• Charles Dimitroff, Ph.D., is a global leader in the study of sugars, known as glycobiology, and is highly motivated to translate glycobiological findings to help cure diseases and improve the overall health of humans. His research focuses on understanding how complex sugars or ‘glycans’ regulate immune and cancer cell functions with the goal of developing new approaches to boost the immune system to fight diseases and to treat cancer progression. As a principal investigator for over 26 years, his efforts have helped identify the nature and impact of glycans on inflammation and cancer, while operating one of the most reputable translational glycobiology programs in the US.

    Dr. Dimitroff has studied the nature of lectin – carbohydrate interactions and their impact in inflammation and cancer for the last 26 years. He has an expertise in glycobiology studies relating to tumor biology and adaptive immunity and is qualified to perform pre-clinical research investigating how glycome-related molecules contribute to the pathogenesis of inflammation and cancer. He conducts both in vitro and in vivo experiments designed to characterize the identity and function of lectins and their carbohydrate-binding ligands on leukocytes and cancer cells.

research interests

  • Cancer glycobiology - melanoma glycobiology; Lymphocyte glyco-immunology; Use of carbohydrate inhibitors, MALDI-TOF-TOF MS/MS of glycans and “homegrown” selectin/ galectin-human Fc chimeras and glycosyltransferase mutant cell lines/mice as glycobiological tools to identity and characterize selectin/galectin ligands functioning in inflammation, tumorigenesis, metastasis, tumor immune evasion and lymphomagenesis
    Native human tissues/cells as sources to isolate the relevant immune/cancer cells.

selected scholarly works & creative activities

full name

  • Charles Dimitroff